Review summary
Teaching objective: Sight-, heart-, limb- and kidney-protecting care for a 52-year-old Black man with long-standing type 2 diabetes who comes in with blurred vision six weeks after the death of his son. The episode covers urgent retina care for proliferative diabetic retinopathy with macular edema and a vitreous hemorrhage (dilated examination, OCT, intravitreal anti-VEGF injections and panretinal photocoagulation, as the AAO Preferred Practice Pattern describes); lowering glucose steadily rather than quickly, with the early worsening of retinopathy after rapid A1c falls and after semaglutide explained and a GLP-1 receptor agonist started only after the retina is stable; an SGLT2 inhibitor for heart and kidney protection; a high-intensity statin with ezetimibe; blood pressure and kidney care; coronary disease found through exertional chest tightness; the ankle-brachial index, foot examination and wound care for a neuropathic heel blister; low-vision services and diabetes tools he can use with poor sight; depression screening and grief support; and the equity of care for a Black man with diabetes complications, under the ADA Standards of Care 2026, the AAO Diabetic Retinopathy Preferred Practice Pattern 2025, the 2024 ACC/AHA PAD and 2023 chronic coronary disease guidelines, and the CMID monographs.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| January 31, 1919 | Born in Cairo, Georgia. | CLM-0001 |
| April 15, 1947 | First major league game, for the Brooklyn Dodgers. | CLM-0002 |
| 1957 | Retirement from baseball announced; diabetes diagnosed at about this time. | CLM-0003, CLM-0005 |
| 1969 | Nerve and artery damage in his legs by this year. | CLM-0006 |
| 1970 | Two mild strokes. | CLM-0007 |
| June 17, 1971 | His eldest son killed in an automobile accident. | CLM-0011 |
| 1972 | Nearly blind, walking with a cane, grieving the deaths of his mentor, mother and son. | CLM-0008, CLM-0009, CLM-0012 |
| October 24, 1972 | Died of a heart attack at his home in Stamford, Connecticut, at 53. | CLM-0013, CLM-0010, CLM-0004 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Jackie Robinson was born on January 31, 1919, in Cairo, Georgia, to a family of sharecroppers. | confirmed | Swaine R. Jackie Robinson (SABR BioProject) supports Assembly Concurrent Resolution No. 197, relative to Jackie Robinson Day (chaptered) supports HISTMED Master Roster v3 context |
| D | On April 15, 1947, he played his first major league game for the Brooklyn Dodgers, ending more than sixty years of segregation in major league baseball. Anchors his identity and his long experience of public pressure in the modern social history. |
confirmed | Swaine R. Jackie Robinson (SABR BioProject) supports Assembly Concurrent Resolution No. 197, relative to Jackie Robinson Day (chaptered) supports |
| D | His retirement from baseball was announced in January 1957; he then worked in business and as a spokesman and fundraiser for civil rights causes, including the NAACP. Anchors his later working life in the modern social history. |
confirmed | Swaine R. Jackie Robinson (SABR BioProject) supports Jackie Robinson Timeline 1950-1979 supports |
| D | He had diabetes and high blood pressure; his death is attributed to heart problems and complications of diabetes. The anchor for the modern diabetes, hypertension and cardiovascular risk. The type and treatment of his diabetes are not given in the sources consulted. |
confirmed | Teaching With Documents: Letter from Jackie Robinson to Roland L. Elliott, April 20, 1972 supports Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) supports Assembly Concurrent Resolution No. 197, relative to Jackie Robinson Day (chaptered) supports |
| D | He was diagnosed with diabetes at about 37, around the time he retired from baseball, and at first kept it private; two of his brothers also had diabetes. Anchors the long duration of diabetes and the family history. Other accounts give other years, and one source says he acknowledged it only a few years after retiring. |
probable | Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) supports Swaine R. Jackie Robinson (SABR BioProject) context |
| D | By 1969, at 50, he had nerve and artery damage in his legs. Anchors the modern peripheral artery disease and neuropathy. Single source. |
probable | Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) supports |
| D | In 1970 he had two mild strokes. Anchors the history of stroke in the modern record. Single source. |
probable | Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) supports |
| D | He lost the sight of one eye and had limited vision in the other; by 1972 he had nearly lost his sight and needed a cane to walk. The anchor for the modern vision-threatening retinopathy. The sources do not date the loss of each eye. |
confirmed | Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) supports Teaching With Documents: Letter from Jackie Robinson to Roland L. Elliott, April 20, 1972 supports |
| R | His loss of vision was most likely caused by diabetic retinopathy; the sources attribute his near-blindness to diabetes and its complications without naming the eye disease. Retrospective interpretation. The grade of retinopathy, macular edema and the hemorrhage in the modern episode are synthetic. |
probable | Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) derived_from Teaching With Documents: Letter from Jackie Robinson to Roland L. Elliott, April 20, 1972 derived_from |
| D | He had several heart attacks; one account counts three, the third of which was fatal. The dates of the earlier ones are not given. Anchors the modern coronary artery disease. Because the earlier heart attacks are not dated, the modern episode records no prior heart attack. |
confirmed | Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) supports Teaching With Documents: Letter from Jackie Robinson to Roland L. Elliott, April 20, 1972 supports |
| D | His eldest son, Jackie Robinson Jr., was killed in an automobile accident on June 17, 1971, at 24. Anchors the bereavement in the modern episode, which begins six weeks later. Circumstances beyond the accident are not used. |
confirmed | Jackie Robinson Timeline 1950-1979 supports Assembly Concurrent Resolution No. 197, relative to Jackie Robinson Day (chaptered) supports |
| D | In his last year he grieved the deaths of his mentor, his mother and his first son. History after the modern episode; supports the weight of grief he carried. |
confirmed | Teaching With Documents: Letter from Jackie Robinson to Roland L. Elliott, April 20, 1972 supports |
| D | He died of a heart attack at his home in Stamford, Connecticut, on October 24, 1972, at 53. History after the modern episode. Anchors his home in Stamford and the cardiovascular teaching objective. |
confirmed | Swaine R. Jackie Robinson (SABR BioProject) supports Assembly Concurrent Resolution No. 197, relative to Jackie Robinson Day (chaptered) supports Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) supports Jackie Robinson Timeline 1950-1979 context |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arranged | resolved | confirmed | active | CLM-0008, CLM-0009 |
| S | Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arranged | resolved | confirmed | active | CLM-0010 |
| S | Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%) | active | confirmed | both_with_link | CLM-0004, CLM-0005 |
| S | Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters left | active | confirmed | both_with_link | CLM-0008, CLM-0009 |
| S | Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasound | active | confirmed | active | CLM-0008, CLM-0009 |
| S | Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg) | active | confirmed | active | CLM-0004, CLM-0005 |
| S | Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79 | active | confirmed | active | CLM-0004, CLM-0005 |
| S | Chronic kidney disease G2 A2 | active | confirmed | active | CLM-0004, CLM-0005 |
| S | Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulses | active | confirmed | both_with_link | CLM-0006 |
| S | Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testing | active | confirmed | both_with_link | CLM-0006 |
| S | History of two mild strokes a year ago, without lasting weakness | active | confirmed | active | CLM-0007 |
| S | Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dL | active | confirmed | active | |
| S | Bereavement: his eldest son died in a car crash six weeks ago | active | confirmed | active | CLM-0011 |
| S | Coronary artery disease with stable angina on climbing stairs: a small reversible inferior perfusion defect on regadenoson stress imaging, ejection fraction 56%; medical therapy chosen with cardiology | active | confirmed | both_with_link | CLM-0010 |
| S | Friction blister of the right heel from new shoes, unroofed, 2.5 by 2 cm, clean base, without infection, in a neuropathic foot with peripheral artery disease | resolved | confirmed | active | CLM-0006 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-07-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 10.4% (high) Reference Below 5.7% is normal; his first goal below 8%, then below 7%, lowered gradually |
http://loinc.org · 4548-4 |
| S | 2026-07-27 | Glucose [Mass/volume] in Serum or Plasma | 248 mg/dL (high) Reference 70-139 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-07-27 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 79 mL/min/1.73 m² (low) Reference 90 or higher is normal; 60 to 89 is mildly decreased (G2) |
http://loinc.org · 98979-8 |
| S | 2026-07-27 | Albumin/Creatinine [Mass Ratio] in Urine | 86 mg/g (high) Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) |
http://loinc.org · 9318-7 |
| S | 2026-07-27 | Cholesterol [Mass/volume] in Serum or Plasma | 226 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-07-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 142 mg/dL (high) Reference Goal below 55 mg/dL with atherosclerotic disease |
http://loinc.org · 13457-7 |
| S | 2026-07-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 mg/dL (low) Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-07-27 | Triglyceride [Mass/volume] in Serum or Plasma | 230 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-07-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-07-27 | Hemoglobin [Mass/volume] in Blood | 13.9 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-07-27 | Platelets [#/volume] in Blood by Automated count | 250 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-07-27 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 380 pg/mL Reference 232-1245 pg/mL |
http://loinc.org · 2132-9 |
| S | 2026-07-27 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-07-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | http://loinc.org · 44261-6 |
| S | 2026-07-29 | Visual acuity best corrected Right eye by ETDRS eye chart | 35 (low) Reference 85 letters is about 20/20; 35 letters is about 20/200 |
http://loinc.org · 79876-9 |
| S | 2026-07-29 | Visual acuity best corrected Left eye by ETDRS eye chart | 56 (low) Reference 85 letters is about 20/20; 55 letters is about 20/80 |
http://loinc.org · 79877-7 |
| S | 2026-07-29 | Macular grid.center subfield thickness by OCT | 412 um (high) Reference 200-300 um |
http://loinc.org · 57109-1 |
| S | 2026-07-29 | Macular grid.center subfield thickness by OCT | 468 um (high) Reference 200-300 um |
http://loinc.org · 57109-1 |
| S | 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 2 | http://loinc.org · 55758-7 |
| S | 2026-09-21 | Total score [AUDIT-C] | 0 | http://loinc.org · 75626-2 |
| S | 2026-08-26 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-08-26 | Potassium [Moles/volume] in Serum or Plasma | 4.8 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-08-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.22 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 71 mL/min/1.73 m² (low) Reference 90 or higher is normal; 60 to 89 is mildly decreased (G2) |
http://loinc.org · 98979-8 |
| S | 2026-08-26 | Ankle-brachial index | 0.68 (low) Reference 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal |
http://loinc.org · 77194-9 |
| S | 2026-08-26 | Ankle-brachial index | 0.74 (low) Reference 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal |
http://loinc.org · 77194-9 |
| S | 2026-10-26 | Hemoglobin A1c/Hemoglobin.total in Blood | 9.2% (high) Reference Below 5.7% is normal; his first goal below 8%, then below 7%, lowered gradually |
http://loinc.org · 4548-4 |
| S | 2026-10-26 | Albumin/Creatinine [Mass Ratio] in Urine | 54 mg/g (high) Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) |
http://loinc.org · 9318-7 |
| S | 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 mL/min/1.73 m² (low) Reference 90 or higher is normal; 60 to 89 is mildly decreased (G2) |
http://loinc.org · 98979-8 |
| S | 2026-10-26 | Cholesterol [Mass/volume] in Serum or Plasma | 150 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-10-26 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 74 mg/dL Reference Goal below 55 mg/dL with atherosclerotic disease |
http://loinc.org · 13457-7 |
| S | 2026-10-26 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-10-26 | Triglyceride [Mass/volume] in Serum or Plasma | 180 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-07-27 | Body height | 180 cm | 8302-2 | S |
| 2026-07-27 | Body weight | 104 kg | 29463-7 | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 32.1 kg/m2 | 39156-5 | S |
| 2026-07-27 | Systolic blood pressure | 152 mm[Hg] | 8480-6 | S |
| 2026-07-27 | Diastolic blood pressure | 92 mm[Hg] | 8462-4 | S |
| 2026-07-27 | Heart rate | 84 /min | 8867-4 | S |
| 2026-07-27 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-27 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-07-29 | Body height | 180 cm | 8302-2 | S |
| 2026-07-29 | Body weight | 103.8 kg | 29463-7 | S |
| 2026-07-29 | Body mass index (BMI) [Ratio] | 32 kg/m2 | 39156-5 | S |
| 2026-07-29 | Systolic blood pressure | 148 mm[Hg] | 8480-6 | S |
| 2026-07-29 | Diastolic blood pressure | 90 mm[Hg] | 8462-4 | S |
| 2026-07-29 | Heart rate | 82 /min | 8867-4 | S |
| 2026-07-29 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-29 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-08-17 | Body height | 180 cm | 8302-2 | S |
| 2026-08-17 | Body weight | 103.2 kg | 29463-7 | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 31.9 kg/m2 | 39156-5 | S |
| 2026-08-17 | Systolic blood pressure | 136 mm[Hg] | 8480-6 | S |
| 2026-08-17 | Diastolic blood pressure | 84 mm[Hg] | 8462-4 | S |
| 2026-08-17 | Heart rate | 64 /min | 8867-4 | S |
| 2026-08-17 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-08-17 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-08-26 | Body height | 180 cm | 8302-2 | S |
| 2026-08-26 | Body weight | 102.8 kg | 29463-7 | S |
| 2026-08-26 | Body mass index (BMI) [Ratio] | 31.7 kg/m2 | 39156-5 | S |
| 2026-08-26 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 2026-08-26 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-08-26 | Heart rate | 60 /min | 8867-4 | S |
| 2026-08-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-08-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-21 | Body height | 180 cm | 8302-2 | S |
| 2026-09-21 | Body weight | 102.2 kg | 29463-7 | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 31.5 kg/m2 | 39156-5 | S |
| 2026-09-21 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-09-21 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-09-21 | Heart rate | 62 /min | 8867-4 | S |
| 2026-09-21 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-26 | Body height | 180 cm | 8302-2 | S |
| 2026-10-26 | Body weight | 101.4 kg | 29463-7 | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 31.3 kg/m2 | 39156-5 | S |
| 2026-10-26 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-10-26 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-26 | Heart rate | 60 /min | 8867-4 | S |
| 2026-10-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Lives in Stamford, Connecticut, with his wife; works in business and in civil rights causes in the region; a former major league ballplayer who broke the color line
- S His eldest son died in a car crash six weeks ago; he says he is carrying it, keeps working, and does not sleep well
- S Tobacco: never. Alcohol: none. No drug use
- S Employer health insurance; medicines affordable with copay assistance for the newer ones
- S Strengths: discipline, a long habit of facing pressure in public, his faith, his work for civil rights, and a household that supports him
Functional status
- S Independent in daily activities; cannot read print or drive safely with his present vision; walks about one block before calf pain stops him
Mental status
- S Alert, direct and composed; grief evident when speaking of his son; no thoughts of self-harm; PHQ-9 score 9
Allergies and medications
Allergies
- S No known allergy
Medications
- S Metformin 1,000 mg oral tablet, one tablet twice daily with meals
- S Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70
- S Lisinopril 20 mg oral tablet, one tablet daily
- S Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake)
- S Aspirin 81 mg delayed-release oral tablet, one tablet daily
- S Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes
- S Metoprolol succinate extended-release 25 mg oral tablet, one tablet daily
- S Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the first
- S Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating
- S Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation
- S Ezetimibe 10 mg oral tablet, one tablet daily
- S Dulaglutide 0.75 mg/0.5 mL pen, one injection under the skin once a week; dose to rise to 1.5 mg after at least four weeks only if the retina remains stable
Procedures and immunizations
Procedures
- S Twelve-lead electrocardiogram
- S Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses
- S Dilated fundus examination of both eyes with B-scan ultrasound of the right eye, at the retina clinic
- S Optical coherence tomography of the macula, both eyes
- S Intravitreal injection of aflibercept 2 mg, both eyes (injection 1)
- S Regadenoson myocardial perfusion stress study, at the cardiology clinic
- S Wound care of the right heel blister by the clinic nurse: cleansing, non-adherent dressing and a heel offloading shoe
- S Intravitreal injection of aflibercept 2 mg, both eyes (injection 2), at the retina clinic
- S Advance care planning conversation, about 20 minutes
- S Optical coherence tomography of the macula, both eyes, at the retina clinic
- S Intravitreal injection of aflibercept 2 mg, both eyes (injection 3), at the retina clinic
- S Panretinal photocoagulation, right eye (first session), at the retina clinic
Immunizations
- S 2026-09-21: Influenza vaccine, inactivated, this season
- S 2026-09-21: Pneumococcal conjugate vaccine PCV20
- S 2026-09-21: Recombinant zoster vaccine, dose 1 of 2
- S 2026-10-26: COVID-19 vaccine, mRNA, this season
- S 2026-10-26: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D about 1957: Diabetes diagnosed at about 37, around his retirement from baseball (CLM-0005)
- D by 1969: Nerve and artery damage in both legs (CLM-0006)
- D 1970: Two mild strokes (CLM-0007)
Family history
- D brother: Two of his brothers had diabetes
- D natural son: His eldest son died in an automobile accident at 24
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Vision kept or improved: proliferative disease regressed and macular edema reduced on anti-VEGF injections and laser | 2026-10-26 | active | Hemorrhage clearing, new vessels regressing after three injections and laser to the right eye; macular thickness down in both eyes; acuity improved |
| A1c falling by about one point every three months without low blood sugar, to below 8% within six months and then below 7% | 2026-10-26 | active | 10.4% to 9.2% at three months; no low blood sugar |
| Blood pressure below 130/80 mmHg | 2026-10-26 | completed | 126/76 in the clinic |
| LDL cholesterol below 55 mg/dL | 2026-10-26 | active | 142 to 74 mg/dL on atorvastatin 80 mg; ezetimibe added |
| Walk at least three blocks without stopping, through supervised exercise | 2026-10-26 | active | From one block to two and a half blocks |
| Feet kept intact: daily foot checks he can do with low vision, protective footwear, and prompt care for any skin break | 2026-10-26 | active | A heel blister found early, healed in five weeks; footwear provided |
| Grief acknowledged and supported, with depression screening repeated | 2026-10-26 | active | Meeting the health center's grief counselor; PHQ-9 9 to 6 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Urgent retina consultation within 48 hours for blurred vision with new floaters in a man with long-standing diabetes: dilated examination, OCT, and treatment of any proliferative retinopathy or macular edema; same-day attendance for a curtain over the vision or flashes | completed | GL-AAO-DR-2025, GL-ADA-RETFOOT-2026 |
| Glucose: continue metformin and basal insulin, titrated slowly by a written plan so that the A1c falls gradually; rescue glucagon; diabetes self-management education adapted for low vision (a talking glucose meter, an insulin pen with audible dose clicks, large-print plans) | completed | GL-ADA-GLY-2026, GL-ADA-PHARM-2026, GL-CMID-2026 |
| Cardiovascular risk: atorvastatin increased to 80 mg, aspirin continued, baseline ECG; cardiology evaluation of exertional chest tightness with a pharmacologic stress test, since calf pain limits walking | completed | GL-ADA-CVD-2026, GL-AHA-CCD-2023, GL-AHA-STROKE-2021, GL-CMID-2026 |
| Legs and feet: comprehensive foot examination today; ankle-brachial index; daily foot checks with a magnifying mirror and a bright lamp, protective shoes; podiatry | completed | GL-ADA-RETFOOT-2026, GL-ACC-PAD-2024 |
| Kidneys: repeat urine albumin and kidney function after any change in kidney medicines; no NSAIDs | completed | GL-ADA-CKD-2026, GL-KDIGO-CKD-2024 |
| Grief and mood: acknowledge the loss, PHQ-9 now and at three months, and an offer of the health center's grief counselor, which he accepted; call or text 988 if thoughts of self-harm ever arise | completed | GL-USPSTF-DEP-2023, GL-ADA-BEH-2026, GL-CMID-2026 |
| Coronary disease, with cardiology: metoprolol succinate 25 mg daily and nitroglycerin as needed; continue high-intensity statin and aspirin; no revascularization now for a small area of ischemia with stable symptoms; review with cardiology in three months or sooner for worse or more frequent chest pain | completed | GL-AHA-CCD-2023, GL-ADA-CVD-2026, GL-CMID-2026 |
| Heel blister: daily dressing by the visiting nurse three times a week and by him on other days with a large-print guide; heel offloading shoe; podiatry within two days; review weekly; a vascular surgery opinion if it is not healing within four weeks or the ankle-brachial index is very low | completed | GL-IWGDF-2023, GL-ACC-PAD-2024, GL-ADA-RETFOOT-2026 |
| On the retina specialist's advice: aflibercept injections in both eyes monthly for three doses, then treat-and-extend; panretinal photocoagulation to the right eye once the hemorrhage clears, and to the left if new vessels persist; vitrectomy if the hemorrhage does not clear within one to three months; low-vision evaluation; aspirin continued; glucose lowered gradually, and a GLP-1 receptor agonist only after the retina is stable, with retina review monthly | completed | GL-AAO-DR-2025, GL-ADA-RETFOOT-2026, GL-SUSTAIN6-2016 |
| Lisinopril increased to 40 mg and empagliflozin 10 mg started, with written sick-day rules; potassium and creatinine in four weeks; urine albumin at three months | completed | GL-ADA-CKD-2026, GL-ADA-CVD-2026, GL-KDIGO-CKD-2024, GL-CMID-2026 |
| Peripheral artery disease: supervised exercise therapy three times a week for twelve weeks once the heel has healed; podiatry every two to three months; vascular review if walking does not improve or any wound fails to heal | completed | GL-ACC-PAD-2024, GL-IWGDF-2023, GL-CMID-2026 |
| Dulaglutide 0.75 mg weekly started with the retina specialist's agreement, rising only if the retina stays stable at monthly review; ezetimibe 10 mg added; lipids four to eight weeks after the change, booked before he leaves the clinic | completed | GL-ADA-PHARM-2026, GL-ADA-CVD-2026, GL-SUSTAIN6-2016, GL-AAO-DR-2025, GL-CMID-2026 |
Planned encounters
- 2026-07-27 — Visit for blurred vision and new floaters, chest tightness on stairs, calf pain on walking and numb feet, in a man with long-standing diabetes six weeks after the death of his son (ENC-001)
- 2026-07-29 — Review after the retina consultation and first eye injections: retinal diagnosis, glucose, blood pressure and kidney medicines (ENC-002)
- 2026-08-17 — Same-day sick visit for a blister on the right heel, and review of the stress test result (ENC-003, unscheduled)
- 2026-08-26 — Four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections (ENC-004)
- 2026-09-21 — Periodic adult preventive visit (ENC-005)
- 2026-10-26 — Three-month review: A1c, urine albumin, lipids, eyes after laser treatment, heart, legs, grief, and a GLP-1 receptor agonist (ENC-006)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Sick Visit
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Ophthalmology (retina) referral
- Ophthalmology (retina) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Sick Visit (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Ophthalmology (retina) referral (XML)
- Ophthalmology (retina) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Swaine R. Jackie Robinson (SABR BioProject) | Society for American Baseball Research | biography |
| SRC-0002 | Assembly Concurrent Resolution No. 197, relative to Jackie Robinson Day (chaptered) | California State Legislature | government |
| SRC-0003 | Teaching With Documents: Letter from Jackie Robinson to Roland L. Elliott, April 20, 1972 | U.S. National Archives and Records Administration | government |
| SRC-0004 | Loeb TB, Morehead-Gee A, Novacek D. Did racism kill Jackie Robinson? (UCLA, republished from The Conversation) | University of California | scholarly |
| SRC-0005 | Jackie Robinson Timeline 1950-1979 | Los Angeles Dodgers (MLB.com) | other |
| SRC-0006 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the urgency of the retina visit, the anti-VEGF and laser sequence, the gradual glucose plan and the timing of dulaglutide after the retina was stable, empagliflozin with lisinopril and the potassium check, the coronary work-up through a pharmacologic stress test, the ankle-brachial index and wound care, and the grief support. |
| provenance review | not_started | Sources: SABR, the California legislature, the National Archives, a University of California article, and the Dodgers timeline. The Library of Congress, the National Baseball Hall of Fame, the Jackie Robinson Foundation, the New York Times obituary and Arnold Rampersad's biography could not be read directly. |
| safe messaging review | not_started | His son's death is stated once, without its circumstances. Grief is supported as grief; depression screening is synthetic and below the threshold for a safety assessment, and the 988 line is named in the plan. No mental health diagnosis is made. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.